<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00124176</url>
  </required_header>
  <id_info>
    <org_study_id>#2004-12-4130</org_study_id>
    <nct_id>NCT00124176</nct_id>
  </id_info>
  <brief_title>Continuous Levalbuterol for Treatment of Status Asthmaticus in Children</brief_title>
  <official_title>Continuous Levalbuterol for Treatment of Status Asthmaticus in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will use a randomized, double-blind, controlled trial design in order to assess
      the safety and efficacy of levalbuterol (LEV) compared to racemic albuterol (RAC) when
      delivered continuously in a high-dose regimen for children with severe exacerbations of
      asthma.

      Primary hypothesis

        -  Children with severe asthma receiving continuous levalbuterol will have a shorter
           duration of continuous therapy as compared to racemic albuterol.

      Secondary hypotheses

        -  Children receiving continuous levalbuterol will have improved lung function measured by
           forced expiratory volume at 1 second (FEV1) as compared to racemic albuterol.

        -  Children receiving continuous levalbuterol will have improved clinical asthma score as
           compared to racemic albuterol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High-dose nebulized albuterol is standard therapy for severe asthma exacerbations at The
      Children's Hospital of Philadelphia (CHOP) and other tertiary care pediatric hospitals
      throughout the United States. For the most severe exacerbations, albuterol is provided
      continuously at high doses until improvement is observed. This regimen has been standardized
      in a treatment protocol that has been used at CHOP for more than 5 years. Recently,
      levalbuterol (LEV), the purified active (R)-enantiomer of albuterol, has been approved for
      use in acute asthma. Preliminary evidence suggests that LEV may improve pulmonary function
      and clinical outcomes in children with asthma based on studies using standard dosing
      regimens. Laboratory and clinical evidence suggest that the (S)-enantiomer of albuterol may
      have detrimental effects that contribute to poor response to racemic albuterol (RAC). Limited
      data exist about the efficacy of LEV in high-dose regimens.

      This study will use a randomized, double-blind, controlled trial design in order to assess
      the safety and efficacy of LEV compared to RAC when delivered continuously in a high-dose
      regimen for severe exacerbations of asthma. Children treated for asthma exacerbations in the
      CHOP emergency department (ED) will be eligible for study enrollment. Those that meet
      enrollment criteria will be randomized to receive either high dose RAC according to the
      standard asthma care protocol or equivalent dosing of LEV. Approximately 128 patients with 64
      in each arm of the study will be enrolled. An interim safety analysis will be conducted after
      the first 40 patients are enrolled. This study should be completed in six to nine months. The
      primary outcome will be duration of continuous therapy. Secondary outcomes will include
      improvement of clinical asthma score and change in forced expiratory volume in one second
      (FEV1). In addition, (R)-albuterol and (S)-albuterol levels will be measured at study entry
      and at 6-hour intervals in the first 40 patients enrolled. These values will be used to
      determine prior RAC exposure and to determine serum levels of (R) and (S) albuterol during
      continuous therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of Continuous Therapy</measure>
    <time_frame>During hospitalization</time_frame>
    <description>standard intention to treat (ITT) analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pediatric Asthma Severity Score</measure>
    <time_frame>After 12 hours of continuous nebulization</time_frame>
    <description>Change in Pediatric Asthma Severity Score. Range 0 (best) - 6 (worst)
Score at each time point is calculated by adding 3 elements:
Wheeze (0= None/Mild, 1=Moderate, 2=Severe) Prolonged expiration (0= None/Mild, 1=Moderate, 2=Severe) Work of breathing (0= None/Mild, 1=Moderate, 2=Severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>After 12 hours of continuous nebulization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Potassium Levels</measure>
    <time_frame>After 12 hours of continuous nebulization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Albuterol S Isomer Levels</measure>
    <time_frame>After 6 hours of continuous albuterol</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulized levalbuterol 10mg/hr given continuously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Racemic albuterol 20mg/hr given continuously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Racemic albuterol (R+S albuterol)</intervention_name>
    <description>20mg/hr continuous racemic albuterol</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levalbuterol (R albuterol)</intervention_name>
    <description>10mg/hr continuous nebulized levalbuterol</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Xopenex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6-18 years of age

          -  Diagnosis of asthma with two previous visits to emergency department (ED) or primary
             care provider for asthma care

          -  Clinical decision by ED attending physician to begin continuous albuterol after
             standardized initial ED treatment.

        Exclusion Criteria:

          -  Clinical decision to begin continuous intravenous beta-agonist infusion (e.g.
             terbutaline)

          -  Clinical decision to admit to the Pediatric Intensive Care Unit

          -  Drug allergy or other contraindication to RAC or LEV

          -  Other concurrent disease such as sickle cell disease, cystic fibrosis, or cardiac
             disease

          -  Pregnancy

          -  Prior enrollment in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph J Zorc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2005</study_first_submitted>
  <study_first_submitted_qc>July 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2005</study_first_posted>
  <results_first_submitted>July 14, 2010</results_first_submitted>
  <results_first_submitted_qc>February 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2013</results_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Levalbuterol</keyword>
  <keyword>Albuterol</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Asthmaticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Continuous Levalbuterol (R) Nebulized Solution</title>
          <description>Continuous levalbuterol nebulized solution 10mg/hr given as continuous nebulization</description>
        </group>
        <group group_id="P2">
          <title>Continuous Racemic (R+S) Albuterol</title>
          <description>Continuous racemic albuterol 20mg/hr given as continuous nebulization</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="37">3 never started on drug due to improvement but were kept in the study by intention to treat.</participants>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Continuous Levalbuterol (R) Nebulized Solution</title>
          <description>Continuous levalbuterol nebulized solution 10mg/hr given as continuous nebulization</description>
        </group>
        <group group_id="B2">
          <title>Continuous Racemic (R+S) Albuterol</title>
          <description>Continuous racemic albuterol 20mg/hr given as continuous nebulization</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="81"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.4" spread="3.5"/>
                    <measurement group_id="B2" value="10.7" spread="3.3"/>
                    <measurement group_id="B3" value="10.6" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of Continuous Therapy</title>
        <description>standard intention to treat (ITT) analysis</description>
        <time_frame>During hospitalization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Levalbuterol (R) Nebulized Solution</title>
            <description>Continuous levalbuterol nebulized solution 10mg/hr given as continuous nebulization</description>
          </group>
          <group group_id="O2">
            <title>Continuous Racemic (R+S) Albuterol</title>
            <description>Continuous racemic albuterol 20mg/hr given as continuous nebulization</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Continuous Therapy</title>
          <description>standard intention to treat (ITT) analysis</description>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="11" upper_limit="25"/>
                    <measurement group_id="O2" value="16" lower_limit="11" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pediatric Asthma Severity Score</title>
        <description>Change in Pediatric Asthma Severity Score. Range 0 (best) - 6 (worst)
Score at each time point is calculated by adding 3 elements:
Wheeze (0= None/Mild, 1=Moderate, 2=Severe) Prolonged expiration (0= None/Mild, 1=Moderate, 2=Severe) Work of breathing (0= None/Mild, 1=Moderate, 2=Severe)</description>
        <time_frame>After 12 hours of continuous nebulization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Levalbuterol (R) Nebulized Solution</title>
            <description>Continuous levalbuterol nebulized solution 10mg/hr given as continuous nebulization</description>
          </group>
          <group group_id="O2">
            <title>Continuous Racemic (R+S) Albuterol</title>
            <description>Continuous racemic albuterol 20mg/hr given as continuous nebulization</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pediatric Asthma Severity Score</title>
          <description>Change in Pediatric Asthma Severity Score. Range 0 (best) - 6 (worst)
Score at each time point is calculated by adding 3 elements:
Wheeze (0= None/Mild, 1=Moderate, 2=Severe) Prolonged expiration (0= None/Mild, 1=Moderate, 2=Severe) Work of breathing (0= None/Mild, 1=Moderate, 2=Severe)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.2"/>
                    <measurement group_id="O2" value="-0.64" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate</title>
        <time_frame>After 12 hours of continuous nebulization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Levalbuterol (R) Nebulized Solution</title>
            <description>Continuous levalbuterol nebulized solution 10mg/hr given as continuous nebulization</description>
          </group>
          <group group_id="O2">
            <title>Continuous Racemic (R+S) Albuterol</title>
            <description>Continuous racemic albuterol 20mg/hr given as continuous nebulization</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate</title>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132" spread="16.4"/>
                    <measurement group_id="O2" value="132" spread="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Potassium Levels</title>
        <time_frame>After 12 hours of continuous nebulization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Levalbuterol (R) Nebulized Solution</title>
            <description>Continuous levalbuterol nebulized solution 10mg/hr given as continuous nebulization</description>
          </group>
          <group group_id="O2">
            <title>Continuous Racemic (R+S) Albuterol</title>
            <description>Continuous racemic albuterol 20mg/hr given as continuous nebulization</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Potassium Levels</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="0.6"/>
                    <measurement group_id="O2" value="3.6" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Albuterol S Isomer Levels</title>
        <time_frame>After 6 hours of continuous albuterol</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Levalbuterol (R) Nebulized Solution</title>
            <description>Continuous levalbuterol nebulized solution 10mg/hr given as continuous nebulization</description>
          </group>
          <group group_id="O2">
            <title>Continuous Racemic (R+S) Albuterol</title>
            <description>Continuous racemic albuterol 20mg/hr given as continuous nebulization</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Albuterol S Isomer Levels</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="3.3"/>
                    <measurement group_id="O2" value="28.6" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Continuous Levalbuterol (R) Nebulized Solution</title>
          <description>Continuous levalbuterol nebulized solution 10mg/hr given as continuous nebulization</description>
        </group>
        <group group_id="E2">
          <title>Continuous Racemic (R+S) Albuterol</title>
          <description>Continuous racemic albuterol 20mg/hr given as continuous nebulization</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Zorc, MD</name_or_title>
      <organization>Children's Hospital of Philadelphia</organization>
      <phone>215-590-1944</phone>
      <email>zorc@email.chop.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

